-+ 0.00%
-+ 0.00%
-+ 0.00%

*Candel Planning to Submit BLA for Aglatimagene Besadenovec in Localized, Intermediate- to High-Risk Prostate Cancer in 4Q

Dow Jones·08/13/2026 12:08:00

Please log in to view news